ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

FWP Forward Pharma AS

1.95
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Name Symbol Market Type
Forward Pharma AS NASDAQ:FWP NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 1.95 1.79 2.12 0 01:00:00

Report of Foreign Issuer (6-k)

12/05/2020 10:01pm

Edgar (US Regulatory)


 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

May 12, 2020

Commission File Number: 001-36686

Forward Pharma A/S

Østergade 24A, 1st Floor
1100 Copenhagen K, Denmark

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes  [   ]  No  [ X ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes  [   ]  No  [ X ]

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes  [   ]  No  [ X ]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  N/A


Item 1.      Issuance of Press Release

On May 12, 2020, Forward Pharma A/S (the “Company”) announced that due to current precautionary measures against the spread of the novel coronavirus, the Technical Board of Appeal of the European Patent Office has rescheduled the oral hearing of the appeal against the decision of the Opposition Division that revoked the EP2801355 patent to February 2, 2021.

The Company has filed as an exhibit to this Form 6-K a press release dated May 12, 2020, announcing the rescheduled hearing date.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

   Forward Pharma A/S
     
     
   
Date: May 12, 2020  By: /s/ Claus Bo Svendsen    
     Name: Claus Bo Svendsen
     Title:   Chief Executive Officer
   

 


EXHIBIT INDEX

 

       
99.1   Press Release dated May 12, 2020
 

1 Year Forward Pharma AS Chart

1 Year Forward Pharma AS Chart

1 Month Forward Pharma AS Chart

1 Month Forward Pharma AS Chart

Your Recent History

Delayed Upgrade Clock